Medical/Pharmaceuticals

A Decade of Persistent Steps, Aspiring for a Thousand Miles: Qyuns' Grand 10th Anniversary Celebration Held Successfully

TAIZHOU, China, June 16, 2025 /PRNewswire/ -- A Decade of Persistent Steps, Aspiring for a Thousand Miles! From June 13th to 14th, 2025, Qyuns' 10th Anniversary Celebration was successfully held in Taizhou. All employees of Qyuns, along with representatives from research institutions, industry p...

2025-06-16 21:14 3794

8th Asia Dengue Summit Renews Call to Achieve Zero Dengue Deaths, with a Record 14 million Global Cases Reported in 2024

Health leaders, researchers, and advocates unite to advance efforts against dengue through innovation, prevention, and cross-sector collaboration. MANILA, Philippines, June 16, 2025 /PRNewswire/ -- As dengue cases in 2024 double to over 14 million globally, with Asia accounting for 70% of the gl...

2025-06-16 17:35 3468

Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241

PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC") CASTRES, France, June 16, 2025 /PRNewswire/ -- Pierre Fabre Laboratories are pleased to announc...

2025-06-16 16:00 2807

Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology

New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announce...

2025-06-16 16:00 2205

NX Malaysia Opens New Batu Kawan Logistics Center near Penang's Batu Kawan Industrial Park

-Nearly 10,000m2 of Warehouse Space Available for Semiconductor, Medical Equipment and Other Companies- TOKYO, June 16, 2025 /PRNewswire/ -- Nippon Express (Malaysia) Sdn, Bhd. (hereafter "NX Malaysia"), a group company of NIPPON EXPRESS HOLDINGS, INC., held a completion ceremony on May 27 to m...

2025-06-16 15:00 2495

Hasten Accelerates Asia-Pacific Expansion with Successful MAT Transfers of 11 Products

SHANGHAI, June 16, 2025 /PRNewswire/ -- Hasten Biopharmaceutical Co., Ltd. ("Hasten") announced today the completion of Market Authorization Transfers (MAT) for 11 major pharmaceutical products across several key Asia-Pacific markets, including Malaysia, Singapore, Philippines, Hong Kong S.A.R. (...

2025-06-16 12:29 3043

The 4th Edition of AMSC Malaysia Returns in 2025: Uniting Global Leaders in Aesthetic Medicine, Dermatology, and Surgery

KUALA LUMPUR, Malaysia, June 16, 2025 /PRNewswire/ -- The Aesthetic Medicine & Surgery Conference & Exhibition (AMSC) returns for its highly anticipated fourth edition on 6–7 August 2025 at the prestigious Kuala Lumpur Convention Centre (KLCC).

2025-06-16 11:30 3053

Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC

SHANGHAI, June 16, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4 inhibitor, for the treatment of Hepatocellular Carcinoma...

2025-06-16 10:47 7502

ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstarys (serdexmethylphenidate/dexmethylphenidate extended-release caps...

2025-06-16 09:00 5525

Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China

SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions , a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a ...

2025-06-14 10:14 6102

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to evaluate the safety and efficacy of the MagicTouch

2025-06-13 19:59 3736

LabConnect Selects Deloitte to Streamline Financial and Business Operations

JOHNSON CITY, Tenn., June 13, 2025 /PRNewswire/ -- LabConnect, a leading provider of global central laboratory and support services for clinical trials, has selected Microsoft Dynamics 365 Finance and Supply Chain, and also engaged Deloitte to transform its enterprise resource planning (ERP) plat...

2025-06-12 23:58 2156

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No. 767762...

2025-06-12 21:17 2358

Gene Solutions and Topgen Join Forces to Advance Precision Oncology All Over China

SHANGHAI, June 12, 2025 /PRNewswire/ -- Gene Solutions has formalized a strategic collaboration with  Zhejiang Shaoxing Topgen Biomedical Technology Co. , Ltd., a CAP-accredited laboratory with a well-established footprint across  all overCh...

2025-06-12 20:14 5619

Reacta Healthcare announces transformation into a facility for multi-allergen manufacturing

* 1st production of pharmaceutical grade egg and milk challenge meals * Product portfolio of challenge meals now includes peanut, milk and egg * Innovation pipeline includes development of 'Top 9' allergen products as well as a products suitable from 6 months DEESIDE, Wales, June 12, 2025 /P...

2025-06-12 19:06 3008

Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC

* 66% of patients surveyed in APAC are experiencing delays in seeing specialist doctor, with an average waiting time of 47 days * 89% of healthcare professionals believe that AI and predictive analytics can save lives by facilitating earlier interventions * Building trust among patients and ...

2025-06-12 12:00 3691

MGI Tech Partners with Asia Pathogen Genomics Initiative to Advance Pathogen Genomics for Public Health in Asia

SINGAPORE, June 11, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and Asia Pathogen Genomics Initiative ("Asia PGI"), part of the Duke-NUS Centre for Outbreak Preparedness (COP), have recently...

2025-06-11 14:36 2923

Fosun International Receives the "ESG & Sustainability Award" and Two Other Prestigious Honors from Global Banking and Finance Review

HONG KONG, June 11, 2025 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656) was recently notified by the renowned British finance magazine,Global Banking and Finance Review, that it has received three awards: "ESG & Sustainability Awards – Best Sustainable Development Company As...

2025-06-11 14:04 4736

Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer

CHENGDU, China, June 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱® ) was...

2025-06-11 11:34 3103

Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology

CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001) evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy we...

2025-06-10 23:52 4049
1 ... 92939495969798 ... 381

Week's Top Stories